Analysis of survival data. (A) OS for all patients treated with rATG and CSA compared with hATG and CSA, including patients who later received an HSCT for nonresponse to ATG. (B) Transplant-free survival for patients treated with rATG and CSA compared with hATG and CSA: transplant is considered an event. (C) OS for patients with SAA treated with rATG and and CSA compared with hATG and CSA, including patients who later received an HSCT for nonresponse to ATG. (D) Transplant-free survival for patients with SAA treated with rATG and CSA compared with hATG and CSA: transplant is considered an event.